Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

EHA-Balkan Hematology Day 2023

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 4th edition of the EHA-Balkan Hematology Day.

Read more

Challenging the safety of conformity: Better poster design to disseminate scientific knowledge fast

“Congratulations – your abstract was accepted for the upcoming EHA congress”.

Read more

Rebuilding the future for hematology in Ukraine today

The Hague (Netherlands), December 5, 2022 - Nearly 8 million Ukrainians have fled their country since February 24 according to the UN Refugee Agency, while about 5 million people have moved back.

Read more

Advances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia

In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

The past and future of the EU Blood, Tissues and Cells legislation

Photo credit: Ineke Oostveen

Blood, tissues and cells (BTC) are used in medicine and in hematology on a daily basis.

Read more